All In Biotech

Drug Trial Radar · NCT04133636

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

68284528MMY2003: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

208

Actual

Start

Nov 7, 2019

Primary completion

Feb 26, 2027

Study completion Aug 25, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 21, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.

Conditions

  • Multiple Myeloma

Interventions

  • JNJ-68284528Drug

    Participants in Cohorts A,B,C, D, E, F and Cohort G (for US sites only) will receive JNJ-68284528 intravenously.

  • LenalidomideDrug

    Some participants in Cohort D and all participants in Cohorts E and Cohort G (for US sites only) will also receive lenalidomide capsules orally.

  • DaratumumabDrug

    Participants in Cohorts E and Cohort G (for US sites only) will also receive daratumumab subcutaneous (SC) injection.

  • BortezomibDrug

    Participants in Cohorts E will also receive bortezomib subcutaneously.

  • DexamethasoneDrug

    Participants in Cohorts E and Cohort G (for US sites only) will also receive dexamethasone orally or intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohorts A, B, C, D, E, and F: Percentage of Participants with Negative Minimal Residual Disease (MRD)Time frame: At least 1 year after JNJ-68284528 infusion on Day 1
  2. For US sites only: Cohort G: Percentage of Participants with Sustained MRD Negative Complete Response (CR)Time frame: At least 1 year after JNJ-68284528 infusion on Day 1

Locations

47 sites in 8 countries. Site status is shown where the registry gives one.

  • University Of California San Diego

    San Diego, California

  • University of California San Francisco

    San Francisco, California

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Moffitt Cancer Center

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Norton Cancer Institute

    Louisville, Kentucky

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Washington University School Of Medicine

    St Louis, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Mount Sinai Medical Center

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Levine Cancer Institute, Carolinas HealthCare System

    Charlotte, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Oregon Health And Science University

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • University of Utah

    Salt Lake City, Utah

  • University of Virginia

    Charlottesville, Virginia

  • Virginia Commonwealth University - Massey Cancer Center

    Richmond, Virginia

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • CHRU de Lille Hopital Claude Huriez

    Lille, France

  • C.H.U. Hotel Dieu - France

    Nantes, France

  • Hopital Saint Louis

    Paris, France

  • Universitaetsklinikum Hamburg Eppendorf

    Hamburg, Germany

  • Universitatsklinikum Wurzburg

    Würzburg, Germany

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.